Phaseline

Companies › Shanghai Fosun Pharmaceutical Industrial Development

Shanghai Fosun Pharmaceutical Industrial Development: clinical trials, targets and expected readouts

9 active drug programs in 12 registered trials: 5 Phase 2, 5 Phase 1, 2 Phase 3; Oncology, Respiratory, Infectious disease, Other; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
FCN-159–Phase 3Neurofibromatosis 1; Langerhans Cell HistiocytosisMay 2027
Foritinib Succinate (SAF-189s)
ALK inhibitor
ALKPhase 3Non-Small Cell Lung CancerDec 2027
XH-S004–Phase 2Non-Cystic Fibrosis Bronchiectasis; Chronic Obstructive Pulmonary DiseaseNov 2026
FCN-338–Phase 2SafetyDec 2026
FXS5626–Phase 2Active Non-anterior, Non-infectious Uveitis; Evaluation of QTc IntervalJan 2027
luvometinib
MEK1/2 inhibitor
MAP2K1Phase 2Non-small Cell Lung CanerJun 2029
XS-04–Phase 1B-cell LymphomaNov 2027
FXS0683
BCL-2 inhibitor
BCL2Phase 1B-Cell LymphomaAug 2028
XS-02–Phase 1Solid TumorMay 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05913037FCN-159Phase 3Neurofibromatosis 1OncologyAug 2025
NCT07035652XH-S004Phase 1Chronic Obstructive Pulmonary DiseaseRespiratoryNov 2026
NCT06858618FCN-338Phase 2SafetyOncologyDec 2026
NCT06981091XH-S004Phase 2Non-Cystic Fibrosis BronchiectasisRespiratoryJan 2027
NCT07695779FXS5626Phase 1Evaluation of QTc IntervalOtherJan 2027
NCT07552012FXS5626Phase 2Active Non-anterior, Non-infectious UveitisInfectious diseaseFeb 2027
NCT05997602FCN-159Phase 2Langerhans Cell HistiocytosisOncologyMay 2027
NCT06820268XS-04Phase 1B-cell LymphomaOncologyNov 2027
NCT06569420Foritinib Succinate (SAF-189s)Phase 3Non-Small Cell Lung CancerOncologyDec 2027
NCT07616089FXS0683Phase 1B-Cell LymphomaOncologyAug 2028
NCT06531486XS-02Phase 1Solid TumorOncologyMay 2029
NCT07562581luvometinibPhase 2Non-small Cell Lung CanerOncologyJun 2029

Targets

BCL2 (1) ALK (1) MAP2K1 (1)

Companies with the same targets

Ascentage Pharma Group Roche Pfizer AbbVie BeOne Medicines Novartis Bio-Path Holdings BeiGene Lomond Therapeutics Holdings Guangzhou Lupeng Pharmaceutical Company

Companies built like this

Shenzhen TargetRx Pierre Fabre Medicament Shanghai Kechow Pharma CStone Pharmaceuticals CSPC Megalith Biopharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.